Consistent time-varying association between ctDNA and post-resection colon and rectal cancer recurrence: The β-CORRECT study

In this retrospective study of 468 patients with Stage II, III, or resectable Stage IV colorectal cancer (CRC), the association between circulating tumor DNA (ctDNA) detected with a tumor-informed molecular residual disease (MRD) assay and recurrence was evaluated. Tumor DNA and RNA sequencing of tumors were also performed to assess associations of tumor genomic alterations and expression with ctDNA status, DFS, and site of recurrence. Among 417 patients with a median follow-up of 1.9 years, ctDNA detection was strongly associated with shorter DFS during surveillance (HR 36.6), post-surgery (HR 7.5) and post-definitive therapy (HR 24.0), independent of clinicopathological factors. Each 10-fold increase in ctDNA level was associated with a two-fold increase in recurrence risk. Median lead time between ctDNA detection and clinical recurrence was 97 days. Among ctDNA-positive patients, adjuvant chemotherapy was associated with improved DFS (HR = 0.3), whereas no benefit was observed among ctDNA-negative patients (HR = 1.8). Significant interactions were observed between ctDNA status and RAS/BRAF alterations and WNT and MAPK pathway alterations. RNA sequencing identified distinct expression patterns associated with the epithelial-mesenchymal transition. These findings support ctDNA as an independent prognostic marker in resected CRC and identify molecular features associated with MRD and recurrence risk.

Authors

Institutions

Publication Details

Journal
Scientific Reports
Published
2026-11-18
DOI
https://doi.org/10.1038/s41598-026-79295-3
Primary Topic
Cancer Genomics and Diagnostics
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Consistent time-varying association between ctDNA and post-resection colon and rectal cancer recurrence: The β-CORRECT study

Yusuke Suwa, 乞宗泰, Judith Frederick, Amin R. Mazloom et al.
4 links
Scientific Reports
Cancer Genomics and Diagnostics
article

Consistent time-varying association between ctDNA and post-resection colon and rectal cancer recurrence: The β-CORRECT study

Yusuke Suwa, 乞宗泰, Judith Frederick, Amin R. Mazloom, Jenny You, Janine R. Lobello, Nishitha Therala, Hiroya Taniguchi, Naoya Akazawa, Ichiro Takemasa, Melanie R. Palomares, Rizi Ai, Paige Innis, Daisuke Kotani, Kozo Kataoka, Martin You, Kentaro Yamazaki, Hideaki Bando, Jorge Garces, David W. Hall, Gregory S. Young, Tara Marti, Masahito Kotaka, Saori Mishima, Eiji Oki, Aimee J. Foreman, Keiji Hirata, Darl D. Flake, Sarah Abdul‐Wajid, Frederick L. Baehner, Daniel Cuevas, Hiromichi Ebi, Gloria Chan Johnson, Satish Seerapu, Somasundaram Subramaniam, S. Lockton, Gargi Dan Basu, Gina L. Costa, Matthew Wallace, Greg Grasse, Garrett Brady, John Hu, 忠美 橋本, Cole Richwine, Michal Wojcik, Mohammad Abbasi, Nila Balendra, Clem Uwimana, Nikolas Delgado, Frankie Garcia-Patrick, Bingbing Song, Mayumi Smyers, Flavio Beas, Benjamin Camptell, Yoshiaki Nakamura, Emad Samani, Exact Sciences MRD Group, Jun Watanabe, Gabriel Fung, Naoki Nariai, Andrea Johnson, Hannah Mooney, Scott Hunicke-Smith, Suzanne Melanson, Jessica Talamante, Takayuki Yoshino, Takeshi Kato, Joseph Rose
article en

Abstract

In this retrospective study of 468 patients with Stage II, III, or resectable Stage IV colorectal cancer (CRC), the association between circulating tumor DNA (ctDNA) detected with a tumor-informed molecular residual disease (MRD) assay and recurrence was evaluated. Tumor DNA and RNA sequencing of tumors were also performed to assess associations of tumor genomic alterations and expression with ctDNA status, DFS, and site of recurrence. Among 417 patients with a median follow-up of 1.9 years, ctDNA detection was strongly associated with shorter DFS during surveillance (HR 36.6), post-surgery (HR 7.5) and post-definitive therapy (HR 24.0), independent of clinicopathological factors. Each 10-fold increase in ctDNA level was associated with a two-fold increase in recurrence risk. Median lead time between ctDNA detection and clinical recurrence was 97 days. Among ctDNA-positive patients, adjuvant chemotherapy was associated with improved DFS (HR = 0.3), whereas no benefit was observed among ctDNA-negative patients (HR = 1.8). Significant interactions were observed between ctDNA status and RAS/BRAF alterations and WNT and MAPK pathway alterations. RNA sequencing identified distinct expression patterns associated with the epithelial-mesenchymal transition. These findings support ctDNA as an independent prognostic marker in resected CRC and identify molecular features associated with MRD and recurrence risk.

Scientific Reports
Kansai Medical University (JP), Kyushu University (JP), Hyogo Medical University (JP), University of Occupational and Environmental Health Japan (JP), Yokohama City University Medical Center (JP), University of Oxford (GB), National Cancer Centre Japan (JP), Shizuoka Cancer Center (JP), Osaka National Hospital (JP), Exact Sciences (United States) (US), Osaka Police Hospital (JP), Sendai Medical Center (JP), Aichi Cancer Center (JP), National Cancer Center Hospital East (JP), Sano Hospital (JP), Sendai City Medical Center (JP), Sendai Open Hospital (JP), Aichi Cancer Center Research Institute (JP), Aichi Cancer Center Hospital (JP)
Japan Agency for Medical Research and Development
Good health and well-being
Cancer Genomics and Diagnostics
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon